Monoclonal glomerulopathy with features of cryoglobulinemic glomerulopathy in murine multiple myeloma model

References

• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152. doi:10.1056/NEJMoa1411321.
   PubMed Web of Science ®Google Scholar
• Yu X, Gan L, Wang Z, Dong B, Chen X. Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: a meta-analysis. Int J Clin Pharmacol Ther. 2015;53(5):391–397. doi:10.5414/CP202245.
   PubMed Web of Science ®Google Scholar
• Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292–4295. doi:10.1182/blood-2012-07-445304.
   PubMed Web of Science ®Google Scholar
• Bridoux F, Leung N, Hutchison CA, et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015;87(4):698–711. doi:10.1038/ki.2014.408.
   PubMed Web of Science ®Google Scholar
• Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15(1):45–59. doi:10.1038/s41581-018-0077-4.
   PubMed Web of Science ®Google Scholar
• Batuman V, Verroust PJ, Navar GL, et al. Myeloma light chains are ligands for cubilin (gp280). Am J Physiol. 1998;275(2):F246–54.
   PubMedGoogle Scholar
• Basnayake K, Stringer SJ, Hutchison CA, Cockwell P. The biology of immunoglobulin free light chains and kidney injury. Kidney Int. 2011;79(12):1289–1301. doi:10.1038/ki.2011.94.
   PubMed Web of Science ®Google Scholar
• Basnayake K, Ying WZ, Wang PX, Sanders PW. Immunoglobulin light chains activate tubular epithelial cells through redox signaling. J Am Soc Nephrol. 2010;21(7):1165–1173. doi:10.1681/ASN.2009101089.
   PubMed Web of Science ®Google Scholar
• Sengul S, Li M, Batuman V. Myeloma kidney: toward its prevention–with new insights from in vitro and in vivo models of renal injury. J Nephrol. 2009;22:17–28.
   PubMed Web of Science ®Google Scholar
• Sengul S, Zwizinski C, Batuman V. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol. 2003;284(6):F1245–54. doi:10.1152/ajprenal.00350.2002.
   PubMed Web of Science ®Google Scholar
• Sengul S, Zwizinski C, Simon EE, Kapasi A, Singhal PC, Batuman V. Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. Kidney Int. 2002;62(6):1977–1988. doi:10.1046/j.1523-1755.2002.00660.x.
   PubMed Web of Science ®Google Scholar
• Li M, Balamuthusamy S, Simon EE, Batuman V. Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells. Am J Physiol Renal Physiol. 2008;295(1):F82–90. doi:10.1152/ajprenal.00091.2008.
   PubMed Web of Science ®Google Scholar
• Li M, Hering-Smith KS, Simon EE, Batuman V. Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells. Nephrol Dial Transplant. 2008;23(3):860–870. doi:10.1093/ndt/gfm670.
   PubMed Web of Science ®Google Scholar
• Ying WZ, Wang PX, Aaron KJ, Basnayake K, Sanders PW. Immunoglobulin light chains activate nuclear factor-kappaB in renal epithelial cells through a Src-dependent mechanism. Blood. 2011;117(4):1301–1307. doi:10.1182/blood-2010-08-302505.
   PubMed Web of Science ®Google Scholar
• Ying WZ, Wang PX, Sanders PW. Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis. Am J Pathol. 2012;180:41–47.
   PubMed Web of Science ®Google Scholar
• Sanders PW. Mechanisms of light chain injury along the tubular nephron. J Am Soc Nephrol. 2012;23:1777–1781.
   PubMed Web of Science ®Google Scholar
• Sirac C, Herrera GA, Sanders PW, et al. Animal models of monoclonal immunoglobulin-related renal diseases. Nat Rev Nephrol. 2018;14(4):246–264. doi:10.1038/nrneph.2018.8.
   PubMed Web of Science ®Google Scholar
• Cheung WC, Kim JS, Linden M, et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest. 2004;113(12):1763–1773. doi:10.1172/JCI200420369.
   PubMed Web of Science ®Google Scholar
• Radl J, Croese JW, Zurcher C, Van den Enden-vieveen MH, de Leeuw AM. Animal model of human disease. Multiple myeloma. Am J Pathol. 1988;132:593–597.
   PubMed Web of Science ®Google Scholar
• Carrasco DR, Sukhdeo K, Protopopova M, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. 2007;11(4):349–360. doi:10.1016/j.ccr.2007.02.015.
   PubMed Web of Science ®Google Scholar
• Chesi M, Robbiani DF, Sebag M, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008;13(2):167–180. doi:10.1016/j.ccr.2008.01.007.
   PubMed Web of Science ®Google Scholar
• Potter M. Neoplastic development in plasma cells. Immunol Rev. 2003;194(1):177–195. doi:10.1034/j.1600-065X.2003.00061.x.
   PubMed Web of Science ®Google Scholar
• Hua Y, White-Gilbertson S, Kellner J, et al. Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma. Clin Cancer Res. 2013;19(22):6242–6251. doi:10.1158/1078-0432.CCR-13-2083.
   PubMed Web of Science ®Google Scholar
• Lai Z, Kumar T, Zhao R, et al. Monoclonal gammopathy of renal significance and its associated experimental models. Ann Clin Lab Sci. 2019;49(4):439–447.
   PubMed Web of Science ®Google Scholar
• Fermand JP, Bridoux F, Kyle RA, et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood. 2013;122(22):3583–3590. doi:10.1182/blood-2013-05-495929.
   PubMed Web of Science ®Google Scholar
• Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387–4390. doi:10.1182/blood-2011-10-388462.
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391–4394. doi:10.1182/blood-2011-11-390930.
   PubMed Web of Science ®Google Scholar
• Leung N, Dispenzieri A, Fervenza FC, et al. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Am J Kidney Dis. 2005;46(2):270–277.
   PubMed Web of Science ®Google Scholar
• Lorenz EC, Gertz MA, Fervenza FC, et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant. 2008;23(6):2052–2057. doi:10.1093/ndt/gfm918.
   PubMed Web of Science ®Google Scholar
• Bridoux F, Hugue V, Coldefy O, et al. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int. 2002;62(5):1764–1775. doi:10.1046/j.1523-1755.2002.00628.x.
   PubMed Web of Science ®Google Scholar
• Guiard E, Karras A, Plaisier E, et al. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol. 2011;6(7):1609–1616. doi:10.2215/CJN.10611110.
   PubMed Web of Science ®Google Scholar